Insider transactions

Francesco De Rubertis

CIK 1601521 · last filed 2026-06-24

Francesco De Rubertis is a corporate insider who has filed 11 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is +$15.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.92M
Companies
3
Total Filings
11
Lifetime Open-Market Net
$15.13M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
C/O MEDICXI
COURS DE RIVE 10
GENEVA CH-1204
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Centessa Pharmaceuticals plc (CNTA) Delisted Director 0 $40.50 $0 $14.43M 6 2026-06-24
NERV Director 586,363 $3.28 $1.92M $699.7K 4 2016-12-14
Aravive, Inc. (VSAR) Delisted Director — — — $0 1 2014-03-24

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-24 Centessa Pharmaceuticals plc (CNTA) Delisted Disp (D) −19,963,157 $0 EDGAR
2022-03-23 Centessa Pharmaceuticals plc (CNTA) Delisted Other (J) +1,839,265 $0 EDGAR
2021-12-06 Centessa Pharmaceuticals plc (CNTA) Delisted Buy (P) +34,326 $440.1K EDGAR
2021-12-02 Centessa Pharmaceuticals plc (CNTA) Delisted Buy (P) +97,151 $1.19M EDGAR
2021-11-30 Centessa Pharmaceuticals plc (CNTA) Delisted Buy (P) +68,523 $797.4K EDGAR
2021-06-04 Centessa Pharmaceuticals plc (CNTA) Delisted Mixed +2,531,818 $12.00M EDGAR
2016-12-14 NERV Exer (X) +202,634 $1.17M EDGAR
2016-08-12 NERV Sell (S) −1,000,000 -$10.00M EDGAR
2015-03-20 NERV Buy (P) +202,634 $974.7K EDGAR
2014-07-09 NERV Mixed +1,796,832 $10.78M EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.